Panbela Therapeutics, Inc. filed a prospectus supplement on August 13, 2024, to update and supplement information in the previously dated prospectus from September 29, 2022, with details from the quarterly report filed on August 13, 2024. The supplement relates to the issuance of 20,100,000 shares of common stock, warrants to purchase up to 30,150,000 shares, and pre-funded warrants to purchase up to 20,100,000 shares. The common stock is quoted on the OTCQB under the symbol 'PBLA' with the last reported sales price being $0.35 per share as of August 12, 2024. The supplement indicates that investing in the securities involves a high degree of risk and should be read in conjunction with the original prospectus. The company's financial statements show a decrease in cash and cash equivalents from $2,578,000 on December...Show More

Panbela Therapeutics, Inc. filed a prospectus supplement on August 13, 2024, to update and supplement information in the previously dated prospectus from September 29, 2022, with details from the quarterly report filed on August 13, 2024. The supplement relates to the issuance of 20,100,000 shares of common stock, warrants to purchase up to 30,150,000 shares, and pre-funded warrants to purchase up to 20,100,000 shares. The common stock is quoted on the OTCQB under the symbol 'PBLA' with the last reported sales price being $0.35 per share as of August 12, 2024. The supplement indicates that investing in the securities involves a high degree of risk and should be read in conjunction with the original prospectus. The company's financial statements show a decrease in cash and cash equivalents from $2,578,000 on December 31, 2023, to $59,000 on June 30, 2024, with a net loss of $14,260,000 for the six months ended June 30, 2024. The company has been subject to losses since its inception in 2011, with a total accumulated deficit of $139,757,000. Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for patients with urgent unmet medical needs, with its lead candidates targeting the polyamine pathway in diseases such as cancer and autoimmunity.